Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer

Yan-Ru Zeng1†, Zhao-Dong Han2†, Cong Wang3†, Chao Cai1, Ya-Qiang Huang1, Hong-Wei Luo1, Ze-Zhen Liu2, Yang-Jia Zhuo1,5, Qi-Shan Dai1, Hai-Bo Zhao4, Yu-Xiang Liang2,7* and Wei-De Zhong1,2,5,6,7*

Abstract

Background: The NIMA-related kinase 2 (NEK2) is a serine/threonine kinase that is involved in regulation of centrosome duplication and spindle assembly during mitosis. Dysregulation of these processes causes chromosome instability and aneuploidy, which are hallmark changes of many solid tumors. However, whether aberrant expression of NEK2 is associated with outcome of prostate cancer (PCa) patients remains to be determined.

Methods: Expression of NEK2 in human PCa cells and primary PCa tissues was assessed by quantitative RT-PCR. Expression of NEK2 in human PCa cells was depleted with siRNA. Effects of the depletion on cell proliferation, survival, and tumorigenicity were assessed both in vitro with cell cultures and in vivo with subcutaneous implantation of xenografts. In silico analyses of the online Taylor dataset were carried out to determine whether the expression level of NEK2 correlated with the clinicopathological characteristics of prostate cancer.

Results: Compared with benign human prostatic epithelial cells and tissues, the expression of NEK2 was elevated in human PCa cells and primary PCa tissues. Depleting NEK2 expression inhibited human PCa cell proliferation in vitro and xenograft growth in vivo. Expression level of NEK2 in PCa positively correlated with the Gleason score and pathologic stage of the patient.

Conclusion: The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa prognosis. Further validation with large sample pool is warrant.

Background

The centrosome is the primary site of microtubule nucleation in cells, which plays a critical role in mitotic spindle formation and chromosome segregation [1, 2]. Normally, cells enter mitosis with two properly duplicated centrosomes. The process ensures bipolarity and correct axial positioning of the spindle. However, cancer cells often exhibit multipolar spindles associating with abnormal centrosome numbers or architectures [3–5]. A number of cell cycle-regulated protein kinases located at the centrosomes have been identified, which are required for mitotic progression and correct bipolar spindle formation [6]. Among them is NIMA-related kinase 2 (NEK2) that has three alternative splice isoforms (NEK2A, NEK2B and NEK2C). The expression of these three isoforms is tightly regulated in a cell cycle-dependent manner, suggesting that they may have isoform-specific roles in mitosis [7, 8].

NEK2 is a constitutive active serine and threonine kinase that phosphorylates multiple proteins involved in centrosome duplication and cell cycle regulation. It binds to microtubules and is enriched in the centrosome, where it contributes to centrosome splitting during the G2/M phase of the cell cycle [9]. Aberrant NEK2 activities cause failure in regulating centrosome duplication, resulting aneuploidy, and, therefore, are oncogenic [10]. Increased NEK2 expression causes premature splitting of centrosomes in human cells. Expression of a kinase-dead mutant of NEK2 induces centrosome abnormalities and
aneuploidy [11, 12]. Similar to other kinases that are involved in spindle assembly or duplication, overexpression of NEK2 has been reported in several neoplastic diseases, such as preinvasive and invasive breast carcinomas [10], lung adenocarcinomas [13], testicular seminomas [14], and diffuse large B cell lymphomas [15]. Overexpression of NEK2 in non-transformed breast epithelial cells induces over duplication of the centrosome [10]. Increased expression of NEK2 causes centrosome amplification in breast cancer cells that express oncogenic K-RAS [16]. Furthermore, NEK2-dependent phosphorylation is required for kinetochore localizations of HEC1, a protein essential for faithful chromosome segregation [17]. In addition, NEK2 is also involved in regulation of viability and apoptosis. Depletion of NEK2 sensitizes HeLa cells to apoptosis and induces alternative splice of SRSF1 target genes [18].

Although a large number of data demonstrate elevated expression as well as reduced stability of NEK2 in cancer cells, whether NEK2 upregulation plays a role in PCa is not clearly. In this study, we investigated expression patterns of NEK2 in tissue microarrays (TMAs) of human PCa and the effect of NEK2 depletion on cell proliferation in PCa cells. The data showed strong correlation of NEK2 expression with the prognostic outcome of PCa patients. Together, our results indicate that NEK2 has a promising value for predicting outcome of PCa recurrence. Future studies with large sample pools are warranted to determine whether the expression level of NEK2 can serve as a biomarkers for PCa prognosis, which still needs prospective validation.

Methods

Patients and tissue samples

The study was approved by the Research Ethics Committee of Guangzhou First People’s Hospital, Guangzhou Medical University, China. An informed consent was obtained from all of the patients. All specimens were handled and remained anonymous according to the ethical and legal standards.

For immunohistochemistry analyses, TMAs with detailed clinical information were purchased from Shanghai Outdo Biotech Co, LTD (Cat#: HPro-Ade180PG-01), which includes 99 primary PCa tissues and 81 adjacent non-cancerous prostate tissues from patients without chemotherapy or radiotherapy before surgery. The Taylor dataset (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21032) contains microarray data for mRNAs from 149 primary PCa tissues and 29 adjacent noncancerous prostate tissues [19]. The dataset contains patient survival time and follow-up examination between from 1 to 175 months with a median of 51 months post-surgery. The date of prostatectomy was considered as day 1 for the survival analyses. The PSA recurrence was defined as three successive PSA rises (final value >0.2 ng/ml), single PSA >0.4 ng/ml, or use of secondary therapy administered for detectable PSA >0.1 ng/ml, which was considered as the biochemical recurrence-free endpoint. The overall survival that was determined from the date of surgery to the time of the last follow-up or death.

Cell culture, transfection, and treatment

For cell viability assays, human PCa LNCaP cells were seeded in 96-well plates (2 × 10^3/well) and cultured for 24, 48, and 72 h. Cells were then incubated with 20 µl CCK-8 solution (Cat No: C0038, Beyotime, China) for 4 h at 37 °C. The absorbance was measured at the wavelength of 495 nm with a spectrophotometer. Data were expressed as mean ± SD of three independent samples. For RNA interference experiments, cells were transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen) according to manufacturer’s instructions and harvested at 24, 48, and 72 h after the transfection for protein and RNA analyses. Sequences of NEK2 siRNAs and scrambled siRNA are listed in Table 1.

Quantitative real-time RT-PCR

Total RNAs were isolated from cells and prostate tissues using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Reverse transcription was carried out using the ReverTra Ace reagents kit (TOYOBO, Osaka, Japan). Real-time RT-PCR was carried out with the MiniOpticon real-time PCR detection system (Bio-Rad, Hercules, CA, USA) using the SYBR Green master mix (Takara, Otsu, Japan). The thermal cycling conditions comprised of one cycle at 94 °C for 4 min, 40 cycles at 94 °C for 15 s, 60 °C for 15 s, and 72 °C for 15 s. All data were analyzed using the Opticon Monitor software (ver3.1, Bio-Rad). The expression of NEK2 was calculated as relative expression level to the GAPDH internal control using the comparative cycle threshold (CT) method. The primer sequences for NEK2 are GCTTAGGTAGGCCCTTTTTCATTTACA and GCC TCAGGTCTATGAACCCCAG. The primer sequences for GAPDH are CATGGGTGTAACCATGAGAAGT and ACAGTAGAGGGCAGGATGTGTTCT.

Table 1. Sequences of the tested NEK2 siRNA targets

| siRNA  | mRNA target                                      |
|--------|-------------------------------------------------|
| Scr    | ATAGTCGTCCACCTCCGC                             |
| NEK2.1 | CGGAGGAAGATGGGACAGATAT                        |
| NEK2.2 | GAAGTGATGGGATGCTACCGATT                      |
| NEK2.3 | GCTGATGAGTATGGCATTAATG                      |
Western blotting analysis
Proteins were extracted 48-hours post-transfection for Western blot analyses. Proteins (40 μg) were fractioned on SDS-PAGE and transferred onto Hybond nitrocellulose membranes (GE Healthcare). The membranes were blocked with 5 % skim milk in PBS-Tween 20 and probed with anti-NEK2 (bs-5732R, Bioss Co Ltd., China) or anti-β-actin antibody (sc-47778, Santa Cruz, USA). The specifically bound antibodies were detected with horse radish peroxidase-conjugated secondary antibody and visualized with the SuperSignal West PICO Chemiluminescent Detection Kit (Pierce Biotechnology). β-actin was used as an internal loading control.

Tumor growth
All nude mice with an average age of 6–8 weeks were purchased from the Guangdong Medical Laboratory Animal Center. The NEK2 silenced cells were injected on the left side flank and the control cells on the right side flank. Briefly, 2×10^6 cells were suspended in 0.1 ml culture medium, and then mixed with Matrigel (BD Biosciences,NO.356234) at the ratio of 1:1. The injections were carried out in a sterilized hood. Five mice per group were used and the experiments were repeated three times. The tumor size was measured with caliper at three time points and the means were calculated. The tumor tissues were harvested at day 43 after the implantation for histology and biochemistry analyses.

Immunohistochemistry analysis
The specimens were fixed in 10 % neutral buffered formalin and subsequently embedded in paraffin. The paraffin-embedded tissues were sectioned at 4 μm thickness and then deparaffinized with xylene and rehydrated for subsequence analyses. For immunohistochemistry staining, the sections were subjected to a brief proteolytic digestion and a peroxidase blocking, the sections were incubated overnight with the primary antibody against NEK2 at a dilution of 1:400, at 4 °C. After washing, the sections were then incubated with peroxidase labeled polymer and substrate–chromogen from DAKO EnVision System (Dako Diagnostics, Switzerland) to detect the specifically bound antibodies as suggested by the manufacturer. No primary antibodies were used as the negative controls. The sections were then lightly counterstained with hematoxylin. The staining was scored by two independent experienced pathologists, who were blinded to the clinicopathological data and clinical outcomes of the patients. The scores of the two pathologists were compared. Any discrepant scores were trained through re-examining the staining by both pathologists to achieve a consensus.

Fig. 1 NEK2 expression and function in prostate epithelial cell lines. a & b Real-time RT-PCR analyses of NEK2 expression in benign human prostatic epithelial cells and PCa cells (a) or NEK2-depleted LNCaP cells. c Western blot analysis for NEK2 protein expression in PrEC and siRNA treated LNCaP cells. d Proliferation analyses of LNCaP cells with or without depletion of NEK2.
score. The number of positive-staining cells in ten representative microscopic fields was counted, and the percentage of positive cells was calculated. The staining was subjected to arbitrative categorized to 5 groups based on the percentage of positive cells for semi-quantitative analyses as following: 0 (0 %), 1 (1–10 %), 2 (11–50 %), 3 (51–80 %) and 4 (>80 %). The staining intensity was visually scored and stratified as follows: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). A final immunoreactivity scores (IRS) were obtained for each case by adding the percentage and the intensity score [20, 21].

Statistical analysis
The statistical analyses was carried out with the SPSS software (Version 13.0 for Windows, SPSS Inc., IL, USA) and SAS 9.1 (SAS Institute, Cary, NC, USA). Continuous variables were expressed as mean ± SD. The

![Image](image-url)
Kaplan–Meier method was used for the survival analyses and a log-rank test was used to analyze the difference of survival. The chiquest trend test was used for ordinal data analysis. Differences were considered statistically significant when \( P \) was smaller than 0.05.

**Results**

**Depleting NEK2 expression reduces cell proliferation in PCa cells**

To determine whether human PCa cells had aberrant NEK2 expression at the mRNA level, quantitative real-time RT-PCR was performed to assess the expression of NEK2 in three human PCa and one benign human prostatic epithelial cell lines. As shown in Fig. 1a, expression of NEK2 was higher in all three PCa cells than in benign human prostatic epithelial cells at the mRNA level, especially in LNCaP cell line. Then we chose LNCaP cells for the further study to determine whether high expression of NEK2 contributed to cell proliferation, siRNA was used to deplete the expression of NEK2 in LNCaP cells. Both real time RT-PCR and Western blot analyses showed that the expression of NEK2 was reduced at both mRNA and protein levels (Fig. 1b&c). Cell proliferation assays demonstrated that LNCaP cells with NEK2 depletion had a lower proliferation rate than the cells transfected with scramble siRNAs (Fig. 1d). The results suggest that high expression of NEK2 promotes cell proliferation.

**Depletion of NEK2 expression suppresses tumorigenicity of LNCaP cells**

To determine whether depletion of NEK2 affected the tumorigenicity of LNCaP cells, the silenced and control cells were implanted to the flanks of the same mice. The tumor sizes were measured at day 14, 23, and 36 post the implantation. It was apparent that tumors derived from NEK2 silenced cells were smaller than those from control cells (Fig. 2a, b&c). The tumors were harvested at day 43 after the implantation for further analyses. In addition to smaller size, the tumors with NEK2 silenced cells were relatively pale than the tumors from control cells (Fig. 2b). Immunostaining revealed that expression of NEK2 protein was reduced compared with the tumors derived from scramble siRNA transfected control cells. High magnification images showed that nuclear and cytosol staining of NEK2 staining was visible in control cells, but was absent in NEK2 depleted cells (Fig. 2d&e). The percentage of NEK2 positive

---

**Fig. 3** Immunohistochemical staining for NEK2 expression in PCa and adjacent non-cancerous tissues (original magnification × 50). a Benign prostate tissue. b PCa with a Gleason score <8. c PCa with a Gleason score ≥ 8. d Statistical analyses showing higher immunoreactivity scores in cancerous tissues than in adjacent non-cancerous tissues. (IRS: Ca = 4.25 ± 1.36 vs Benign = 2.93 ± 1.51, \( P =0.03 \)). a, b, and c were from TMA sample NO. A5, J8, and H8, respectively.
cells was dramatically decreased in NEK2 siRNA group (Fig. 2f).

The expression level of NEK2 is associated with the clinicopathological characteristics of PCa and tumor recurrence time of PCa patients

We then analyzed the expression pattern and localization of NEK2 in a PCa TMA comprised of 99 PCa and 81 adjacent non-cancerous prostate tissues by immunohistochemistry staining. Representative pictures of immunohistochemistry staining of NEK2 are shown in Fig. 3a-c. NEK2 immunostaining was weak or undetectable in adjacent noncancerous prostate tissues (Fig. 3a). In contrast, strong staining of NEK2 was readily seen in the cytoplasm and nucleus of PCa tissues (Fig. 3b-c). A summary of NEK2 immunostaining in PCa tissues was shown in Table 2. Apparently, the PCa with a Gleason Score $\geq 8$ had higher NEK2 expression than those with a Gleason Score $<8$. In addition, the PCa at high pathological stages showed increased NEK2 expression compared with PCa at low pathological stages. Moreover, statistical analyses of the Taylor dataset also showed that PCa with a Gleason Score $\geq 8$ had higher expression of NEK2 than those with a Gleason Score $<8$ ($P = 0.011$) at the mRNA level. In addition, overexpression of NEK2 was also associated with metastasis, PSA failure, and overall survival time of patient, although no correlation between NEK2 expression at the mRNA level and pathological stages was seen in the Taylor dataset (Table 2).

We then use the Kaplan–Meier method to analyze the association of NEK2 expression levels with the biochemical recurrence-free time and the overall survival time of PCa patients. The median of NEK2 expression in all PCa tissues of the Taylor dataset was used as the cutoff to divide all PCa tissues into high ($n = 80$) and low ($n = 80$) NEK2 expression groups. As shown in Fig. 4, the biochemical recurrence-free time of PCa patients with high NEK2 expression levels was shorter than those with low NEK2 expression levels. However, no correlation of the overall survival time of PCa patients with NEK2 expression levels was seen.

**Discussion**

PCa affects one in nine men over the age of 65 and is the most frequently diagnosed cancer in American males [22, 23]. Early diagnosis through detection of serum prostate specific antigen (PSA) and improved procedures for surgical intervention and radiation therapy have significantly reduced the number of fatalities [24–27].

### Table 2 Association of NEK2 expression with the clinicopathological characteristics of prostate cancer

| Clinical feature       | IRS of NEK2 in our cohort | NEK2 expression in Taylor dataset |
|------------------------|----------------------------|-----------------------------------|
|                        | Case | $X \pm s$ | $p$                          | Case | $X \pm s$ | $p$                          |
| Age(years)             |      |           |                              |      |           |                              |
| <71 years              | 85   | 3.67 ± 1.43 | 0.904                        | 146  | 7.54 ± 0.29 | 0.717                        |
| $\geq$ 71 years        | 95   | 3.64 ± 1.70 | 4                             | 7.48 ± 0.26 | 0.440                        |
| Serum PSA              |      |           |                              |      |           |                              |
| <4 (ng/ml)             | 24   | 7.58 ± 0.32 | 0.440                        |      |           |                              |
| $\geq$ 4 (ng/ml)       | 123  | 7.53 ± 0.29 | 0.29                         |      |           |                              |
| Gleason score          |      |           |                              |      |           |                              |
| <8                     | 70   | 3.81 ± 1.08 | <0.001                       | 117  | 7.48 ± 0.25 | 0.011                        |
| $\geq$ 8               | 28   | 5.36 ± 1.39 | 22                           | 7.71 ± 0.37 | 0.063                        |
| Pathological Stage     |      |           |                              |      |           |                              |
| T2                     | 70   | 3.81 ± 1.08 | <0.001                       | 86   | 7.48 ± 0.23 | 0.063                        |
| T3                     | 29   | 5.31 ± 1.39 | 55                           | 7.58 ± 0.35 | <0.001                       |
| Metastasis             |      |           |                              |      |           |                              |
| No                     | 99   | 4.25 ± 1.35 | -                            | 122  | 7.47 ± 0.25 | <0.001                       |
| Yes                    | 0    | -          | 28                           | 7.81 ± 0.33 | 0.086                        |
| Overall survival       |      |           |                              |      |           |                              |
| Alive                  | -    | -          | 131                          | 7.51 ± 0.27 | 0.086                        |
| Die                    | -    | -          | 19                           | 7.68 ± 0.38 | -                            |
| PSA failure            |      |           |                              |      |           |                              |
| Negative               | -    | -          | 104                          | 7.46 ± 0.25 | <0.001                       |
| Positive               | -    | -          | 36                           | 7.66 ± 0.31 | -                            |
However, there is still no effective cure for men with advanced PCa that is often castration-resistant. Many studies have been dedicated to identifying prognostic markers that can be used to distinguish indolent versus aggressive forms of PCa. NEK2 is a centrosomal locating serine/threonine kinase required for centrosome duplication in mitosis. Expression of NEK2 is frequently upregulated in human cancers [9]. Recent evidence suggests that nuclear localization of NEK2 represents a strong predictor for drug resistance and poor prognosis in cancer [28]. Therefore, inappropriate high expression of NEK2 might interfere with either centrosome integrity or chromosome segregation. However, the underlying cause for the increase in NEK2 expression is still unclear. This has led to a hypothesis that deregulation of centrosome function could be a major contributory factor to the genetic instability and loss of tissue differentiation that drive most cancer progression. Similar findings from other study indicate that aberrant expression and activity of NEK2 drive the progression and transformation of lymphomas that ultimately causes a more aggressive disease [31]. Specifically, overexpression of NEK2 in the ARP-1 multiple myeloma cells causes reduced treatment efficacy of bortezomib, doxorubicin, and etoposide [28]. Downregulation of NEK2 by shRNA inhibited myeloma cell growth and decreased drug resistance in vitro and in NOD-Rag/null gamma mice [19]. Paclitaxel and doxorubicin in combination with Nek2 siRNA or ASO treatment promote breast cancer cell apoptosis [36].

In summary, we reported that NEK2 was highly expressed in PCa cells and tissues. Depletion of NEK2 inhibited proliferation and tumorigenicity of the cells. In addition, expression of NEK2 was associated with poor outcome of PCa patients. Thus, the expression level of NEK2 has the potential for predicting PCa progression. A large study with more patient pool is warranted to determine whether expression of NEK2 can serve as a biomarker for PCa diagnosis and prognosis.

Conclusions

The findings demonstrate that the overexpression of NEK2 is associated with progression in PCa and suggest that NEK2 has the potential to serve as a biomarker for PCa prognosis. Further validation with large sample pool is warrant.

Abbreviations

NEK2: NIMA-related kinase 2; PCa: Prostate cancer; PSA: Prostate specific antigen; TMA: Tissue microarray.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CW, ZDH, YXX, and WDD participated in study design and coordination, analysis and interpretation of data, material support for obtained funding, and supervised study. YRZ, YQH and ZLL performed most of the experiments and statistical analysis and drafted the manuscript. Other authors: carried out the experiment and sample collection. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by grants from National Natural Science Foundation of China (81170699, 81272813, 81270761, and 81101712), Projects of Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou Medical Key Subject Construction Project.

Author details
1. Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou 510515, China. 2. Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 510180, China.
3. School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China.
4. Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510799, China.
5. Department of Urology, Huaudu District People’s Hospital, Southern Medical University, Guangzhou 510800, China.
6. Urology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510230, China.
7. University of Guangzhou, First People’s Hospital, Guangzhou Medical University, Guangzhou 510180, China.

Received: 28 January 2015 Accepted: 19 August 2015
Published online: 29 August 2015

References
1. Doxsey S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol. 2001;2(9):988–98.
2. Bornens M. Centrosome composition and microtubule anchoring mechanisms. Curr Opin Cell Biol. 2002;14(2):25–34.
3. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quensenbery P, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998;58(17):3974–85.
4. Lingle WL, Lutz WH, Ingle JJ, Mahie NJ, Salisbury JJ. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A. 1998;95(6):2950–5.
5. Pihan GA, Purohit A, Wallace J, Malhotra R, Lupp A, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 2001;61(5):2212–9.
6. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2(1):1–32.
7. Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene. 2002;21(40):5184–94.
8. Hames RS, Fry AM. Alternative splice variants of the human centrosomal kinase Nek2 exhibit distinct patterns of expression in mitosis. Biochem J. 2002;36(1):57–77.
9. Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett. 2006;237(2):155–66.
10. Hayward DG, Clarke BB, Faragher AJ, Pillar MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 2004;64(20):7370–6.
11. Fry AM, Menaldi L, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J. 1998;17(2):870–81.
12. Faragher AJ, Fry AM. Nek2A kinase stimulates centrosome dysfunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell. 2003;14(7):2876–89.
13. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE. 2008;3(2):e1651.
14. Barbagallo F, Paronetto MP, Franco R, Cheffi P, Dolci S, Fry AM, et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol. 2009;217(3):431–41.
15. Andreasen U, Dørtor, Mørk M, Berglund M, Sundstorm C, Linderoth J, et al. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Ann J Hematol. 2009;84(1):893–8.
16. Zeng X, Shikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, et al. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene. 2010;29(36):5103–12.
17. Chen Y, Riley DJ, Zheng L, Chen PL, Lee WH. Phosphorylation of the mitotic regulator protein HeC1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem. 2002;277(51):49948–56.
18. Naro C, Barbagallo F, Cheffi P, Bourgeois CF, Paronetto MP, Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res. 2014;42(3):3218–27.
19. Taylor BS, Schulz N, Heirynus H, Gopalani A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.
20. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathol. 1987;38(1):38–40.
21. Kaeberer D, Lü P, Lupp A, Schulz S, Sanger J, Baum RP, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(2):1824–30.
22. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000;14(19):2410–34.
23. Ruijter E, van de Kaa C, Miller G, Debruyne F, Schalkgen J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999;20(1):22–45.
24. Peskoe SB, Jordan CE, Rohrman S, McGlynn KA, Nyante SJ, Bradwin G, et al. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015;75(11):1167–76.
25. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2015. doi:10.1016/j.eururo.2015.05.009.
26. Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Eser T. Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process. Prostate. 2015;75(7):748–57.
27. Hoyer M, Muren LP, Gilmebelus B. The evolution of radiotherapy techniques in the management of prostate cancer. Acta Oncol. 2015;54(9):821–4.
28. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, et al. Nek2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48–62.
29. Matsuhashi A, Onho T, Kimura M, Hara A, Saio M, Nagano A, et al. Growth suppression and mitotic defect induced by JNU-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012;12(6):625–39.
30. Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of Nek2 is associated with drug resistance in ovarian cancer. Oncol Rep. 2014;31(2):745–54.
31. de Vos S, Hofmann WK, Grogan TM, Krug J, Schrage M, Miller TP, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest. 2003;83(2):271–85.
32. Cappello P, Blaser H, Gerini C, Lin DC, Elia AJ, Wakeham A, et al. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene. 2014;33(18):2375–84.
33. Koch M, Wiese M. Gene expression signatures of angioid and drapahid treatment connect to therapy options in cervical cancer. J Cancer Res Clin Oncol. 2013;139(2):259–67.
34. Twomey C, Wattam SL, Pillar MR, Rapley J, Baxter JE, Fry AM. Nek2B stimulates zygotic centrosome assembly in Xenopus laevis in a kinase-independent manner. Dev Biol. 2004;265(2):384–98.
35. Uto K, Sagata N. Nek2B, a novel maternal form of Nek2 kinase, is essential for neurogenesis in zebrafish embryos. EMBO J. 2000;19(8):2016–26.
36. Lee J, Gollahon L. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells. Int J Oncol. 2013;42(3):839–47.